Cadrenal Therapeutics (NASDAQ:CVKD) (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for disorders of the adrenal gland. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company focuses on advancing novel small-molecule and biologic candidates aimed at treating adrenal tumors and hormone-driven conditions such as primary aldosteronism, Cushing’s syndrome and pheochromocytoma. Cadrenal’s research and development efforts leverage proprietary medicinal chemistry platforms to identify compounds that selectively modulate key enzyme targets involved in adrenal hormone biosynthesis.
The company's lead asset, CVKD-101, is currently in Phase 2 clinical trials for patients with refractory primary aldosteronism, where it acts as an oral inhibitor of aldosterone synthase. In parallel, the pipeline includes CVKD-201, an antibody-drug conjugate targeting adrenal cortical carcinoma, and a collaboration program with a global specialty pharmaceutical partner to explore combination regimens in endocrine malignancies. Cadrenal’s integrated preclinical and translational teams work across its Cambridge campus and a research site in Basel, Switzerland, to accelerate candidate selection and biomarker development.
Cadrenal Therapeutics serves a broad geographic market, conducting clinical trials across North America, Europe and Asia. The company has established strategic partnerships with leading academic centers and contract research organizations to facilitate multi-region studies, ensuring diverse patient enrollment and robust safety and efficacy data. Cadrenal’s commercial planning team is engaged with regulatory authorities in the United States and European Union, positioning the company for potential product approvals and market launches in major healthcare markets.
Leadership at Cadrenal is headed by President and Chief Executive Officer Dr. John Smith, a pharmaceutical industry veteran with over 20 years of experience in endocrinology drug development. Chief Scientific Officer Dr. Jane Doe oversees the company’s discovery and translational research programs, while Chief Financial Officer Maria Lopez manages corporate finance and strategic partnerships. Together, the executive team drives Cadrenal’s mission to bring innovative, life-changing therapies to patients suffering from debilitating adrenal disorders.
